IL6 and graft versus host disease: In addition, vorinostat increased Treg cell numbers, upregulated the expression of CD45RA and CD31 on Treg cells [24], and downregulated IL-6 and GVHD biomarkers, including soluble ST2 and Reg3a, resulting in a low incidence of aGVHD [25].